Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Postmenopausal Osteoporosis

Postmenopausal Osteoporosis

Part of Osteoporosis

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Postmenopausal Osteoporosis

60 trials tracked for Postmenopausal Osteoporosis: 41 in phase 3 or 4 and 13 with published results. The most-cited published study has 602 citations.

60Trials tracked
41Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 4 14 Phase 3 27 Phase 2 8 Phase 1 5 Other / NA 6
  1. Phase 4 VERtebral Fracture Treatment Comparisons in Osteoporotic Women Completed · 602 cited
  2. Phase 3 An Open-label Study to Evaluate the Effect of Treatment With Romosozumab or Teriparatide in Postmenopausal Women Completed · 495 cited
  3. Phase 3 Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis Completed · 214 cited
  4. Phase 3 Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis Completed · 177 cited
  5. Phase 4 Alterations of GCF Levels of Sclerostin and DKK-1 in Postmenopausal Osteoporosis Completed · 160 cited
  6. Phase 4 Denosumab and Teriparatide Study (DATA-HD and DATA-EX) Completed · 71 cited
Show 44 more trials
  1. Phase 3 Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women Completed · 48 cited
  2. Phase 3 Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption Completed · 41 cited
  3. Phase 3 A Safety and Efficacy Study to Evaluate Romosozumab (AMG 785) in South Korean Women With Osteoporosis Completed · 28 cited
  4. Phase 3 Efficacy & Safety of Abaloparatide-Solid Microstructured Transdermal System in Postmenopausal Women With Osteoporosis Completed · 24 cited
  5. Phase 3 A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis Completed · 12 cited
  6. Phase 4 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed · 8 cited
  7. Phase 3 Multicenter Study in Postmenopausal Women With Osteoporosis, ALVOBOND Completed · 4 cited
  8. Phase 4 A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis. Completed
  9. Phase 4 A Study of Adherence to Once Monthly Ibandronate (Bonviva) in Women With Post-Menopausal Osteoporosis, Supported by a Patient Relationship Program (PRP) Completed
  10. Phase 4 The Effects of Potassium Citrate on Bone Metabolism Completed
  11. Phase 4 Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis Completed
  12. Phase 4 Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration Completed
  13. Phase 4 Zoledronic Acid for Osteoporotic Fracture Prevention (ZEST II) Completed
  14. Phase 4 Preventing Osteoporosis Using Denosumab Completed
  15. Phase 4 A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide Completed
  16. Phase 4 Efficacy and Safety Study of Fosamax Plus D in Postmenopausal Women With Osteoporosis (0217A-263) Completed
  17. Phase 4 A Study to Evaluate Alendronate Sodium /Vitamin D3 Combination Tablets(FOSAMAX PLUS) Versus Calcitriol in the Treatment of Osteoporosis in Postmenopausal Women in China (MK-0217A-264) Completed
  18. Phase 3 Denosumab China Phase III Study Completed
  19. Phase 3 A Double-blind Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis Completed
  20. Phase 3 A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis Completed
  21. Phase 3 A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis Completed
  22. Phase 3 Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis Completed
  23. Phase 3 A Study to Evaluate the Efficacy, Pharmacodynamics, Safety, and Immunogenicity of FKS518 in Postmenopausal Women With Osteoporosis Completed
  24. Phase 3 A Phase 3 Study to Compare Biosimilar Denosumab With Prolia® Completed
  25. Phase 3 A Study in Korean Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed
  26. Phase 3 Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis Completed
  27. Phase 3 A Study Comparing Oral Calcitonin to Nasal Spray Calcitonin in Postmenopausal Osteoporotic Women Completed
  28. Phase 3 A Study to Evaluate the Safety and Efficacy of Denosumab and Ibandronate in Postmenopausal Women Sub-Optimally Treated With Daily or Weekly Bisphosphonates Completed
  29. Phase 3 A Study of Monthly Risedronate for Osteoporosis Completed
  30. Phase 3 A Study in Indian Postmenopausal Women With Osteoporosis to Evaluate the Efficacy and Safety of Denosumab Completed
  31. Phase 3 Efficacy and Safety Study on Menatetrenone in the Treatment of Postmenopausal Osteoporosis Women Completed
  32. Phase 3 Study of Transitioning From Alendronate to Denosumab Completed
  33. Phase 3 A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab Completed
  34. Phase 3 Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis Completed
  35. Phase 3 A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis Completed
  36. Phase 2 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women Completed
  37. Phase 2 Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022) Completed
  38. Phase 2 Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women Completed
  39. Phase 2 A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density Completed
  40. Phase 2 MK-5442 in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated With an Oral Bisphosphonate (MK-5442-012) Completed
  41. Phase 2 Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density Completed
  42. Phase 2 Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of PTH Analog Tablets in Postmenopausal Women Completed
  43. Phase 2 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab Completed
  44. Phase 1 A Multiple-Dose Study to Evaluate Skin Irritation and Sensitization of Teriparatide Administered Transdermally in Healthy Postmenopausal Women Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Postmenopausal Osteoporosis: what the trials found

New clinical evidence identifies ENZ215 as a treatment for postmenopausal osteoporosis 1.

Teriparatide significantly reduces the incidence of new vertebral fractures (p=0.000094), pooled new and worsening vertebral fractures (p=0.000075), and pooled clinical vertebral and non-vertebral fragility fractures (p=0.000869) 2.

Denosumab is associated with significant increases in spine bone mineral density (BMD) 4 and improvements in total hip BMD 6 and spine BMD 6.

Romosozumab demonstrates significant efficacy in reducing the incidence of new vertebral fractures at 12 months (p<0.001) and 24 months (p<0.001), as well as clinical fractures at 12 months (p=0.008) 18. It also significantly increases BMD at the lumbar spine, total hip, and femoral neck [16, 21].

Abaloparatide is associated with significant increases in mineralizing surface/bone surface (MS/BS) in the cancellous envelope 20, as well as significant increases in lumbar spine, total hip, and femoral neck BMD at 12 months 22.

Alendronate combinations show significant improvements in lumbar spine BMD at both 6 and 12 months 13 and significantly higher gains in total hip, femoral neck, and lumbar spine BMD compared to other cohorts 17. Alendronate with cholecalciferol was associated with a reduction in patients with serum 25-hydroxyvitamin D below deficiency levels (p<0.0001) and significant changes in Serum PTH 15.

Ibandronate is associated with high patient adherence rates (98.5%) and high scores in patient satisfaction surveys 11. Patients also showed a preference for once-monthly dosing over once-weekly dosing based on convenience of administration (p<0.0001) 9.

Placebo groups showed significant increases in lumbar spine BMD compared to other cohorts at 6 and 12 months 12, while a separate placebo study showed significantly lower rates of new vertebral fractures compared to an intervention group 19.

Recent results — preliminary, needs further review

  • ENZ215 is identified as a new treatment for postmenopausal osteoporosis 1.

For the clinician treating this condition

  • Teriparatide, Romosozumab, and Abaloparatide are associated with significant reductions in fracture incidence or substantial increases in bone mineral density across multiple sites.
  • Denosumab and Alendronate (with various co-treatments) provide statistically significant improvements in spine and hip BMD.
  • Ibandronate is associated with high patient satisfaction and adherence, particularly when administered in a once-monthly dosing regimen.

AI synthesis of 14 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Higher Geriatric Nutritional Risk Index linked to lower osteoporosis risk in diabetic women
Diabetes & Endocrinology Cohort
Higher Geriatric Nutritional Risk Index linked to lower osteoporosis risk in diabetic women Better nutrition linked to lower osteoporosis risk in women with diabetes
This retrospective observational cohort study of 324 postmenopausal women with type 2 diabetes found that a higher Geriatric Nutritional Ris…
A simple nutrition score may help spot osteoporosis risk in women with type 2 diabetes, new hospital data suggests.
Frontiers Apr 22, 2026

Research across Osteoporosis

Related studies from across the Osteoporosis family.

Gut microbiota and its products regulate bone metabolism through the gut-immune-bone axis
Orthopedics & Sports Medicine Sys. Review
Gut microbiota and its products regulate bone metabolism through the gut-immune-bone axis Gut health and bacteria may play a role in bone health
This narrative review explores the role of gut microbiota and products like short-chain fatty acids and tryptophan catabolites in bone metab…
New research suggests that the bacteria in your gut and their byproducts may directly influence how your bones stay strong and healthy.
Frontiers Oct 27, 2026
Immunosenescence drives pro-inflammatory immune shifts and impaired bone remodeling in osteoporosis
Orthopedics & Sports Medicine Sys. Review
Immunosenescence drives pro-inflammatory immune shifts and impaired bone remodeling in osteoporosis Aging immune systems may drive bone loss in osteoporosis
This systematic review examines the impact of immunosenescence on bone remodeling and immune cell function in osteoporosis. The authors synt…
Aging causes changes in immune cells that can weaken bones and promote osteoporosis, opening new doors for immune-centered treatments.
Frontiers Oct 22, 2026
Efficacy of Chinese Polyherbal Preparations Combined with Biomedicine for Diabetic Osteoporosis
Drug Pipeline Meta-analysis
Efficacy of Chinese Polyherbal Preparations Combined with Biomedicine for Diabetic Osteoporosis Herbal additions may improve outcomes for patients with diabetic osteoporosis
A network meta-analysis suggests that integrating specific Chinese polyherbal preparations with standard care improves bone density and gluc…
Combining specific herbal preparations with standard medicine may improve bone density and blood sugar for people with diabetic osteoporosis…
Frontiers Oct 22, 2026
RAAS inhibitors modulate inflammatory responses and oxidative stress across multiple chronic conditions
Drug Pipeline Sys. Review
RAAS inhibitors modulate inflammatory responses and oxidative stress across multiple chronic conditions RAAS Inhibitors May Protect Organs Beyond Lowering Blood Pressure
This systematic review synthesizes the roles of ACEI, ARB, DRI, ARNI, and MRA in modulating inflammatory responses and oxidative stress. The…
New research suggests certain blood pressure medications may protect the heart, kidneys, and lungs by reducing inflammation and oxidative st…
Frontiers Oct 16, 2026
Microbiota-directed interventions show inconsistent clinical efficacy for reducing fracture risk in osteoporosis
Orthopedics & Sports Medicine Sys. Review
Microbiota-directed interventions show inconsistent clinical efficacy for reducing fracture risk in osteoporosis Gut Health May Play a Role in Bone Density
This narrative review synthesizes preclinical and observational data regarding the gut-bone axis and the role of probiotics and synbiotics i…
New research explores how gut bacteria and probiotics might influence bone health and fracture risk in people with osteoporosis.
Frontiers Oct 15, 2026
Chinese osteoporosis management guidelines show consensus on diagnosis but vary in specific treatment recommendations
Diabetes & Endocrinology Meta-analysis
Chinese osteoporosis management guidelines show consensus on diagnosis but vary in specific treatment recommendations Chinese Osteoporosis Guidelines Often Disagree, Review Finds
This systematic review of 32 Chinese guidelines identifies consensus on osteoporosis definitions and diagnostic criteria. However, significa…
A review of 32 Chinese osteoporosis guidelines found broad agreement on basics but sharp splits on specific treatments.
Frontiers Oct 15, 2026
Chinese clinical practice guidelines for osteoporosis demonstrate moderate methodological and recommendation quality scores
Diabetes & Endocrinology Meta-analysis
Chinese clinical practice guidelines for osteoporosis demonstrate moderate methodological and recommendation quality scores Chinese Osteoporosis Guidelines Fall Short on Rigor, Review Finds
This systematic review evaluates the methodological rigor and recommendation quality of 13 Chinese clinical practice guidelines for osteopor…
A review of 13 Chinese osteoporosis guidelines found wide gaps in how rigorously they were developed, with some scoring as low as 25%.
Frontiers Oct 15, 2026
German translation and adaptation of the APTA Geriatrics guideline provides a basis for evidence-based physiotherapy
Geriatrics & Aging Meta-analysis
German translation and adaptation of the APTA Geriatrics guideline provides a basis for evidence-based physiotherapy New German Translation Provides Guidance for Osteoporosis Physical Therapy
This translation and adaptation of a clinical practice guideline adapts the 2022 APTA Geriatrics guideline for the German healthcare context…
A new German translation of the APTA Geriatrics guidelines provides a clear framework for physical therapy and exercise for patients with os…
Frontiers Oct 14, 2026
Gut microbiota and metabolic products regulate bone homeostasis and immune checkpoints in osteoporosis
Orthopedics & Sports Medicine Sys. Review
Gut microbiota and metabolic products regulate bone homeostasis and immune checkpoints in osteoporosis Gut Health May Play a Key Role in Bone Health
This systematic review explores the gut-immune-bone axis, highlighting how gut microbiota and metabolites like short-chain fatty acids and t…
New research suggests that the bacteria in your gut may help regulate bone health and could offer new ways to manage osteoporosis.
Frontiers Oct 12, 2026
Exercise improves balance function in patients with osteoporosis with larger effects for longer durations
Physical Medicine & Rehab Meta-analysis
Exercise improves balance function in patients with osteoporosis with larger effects for longer durations Exercise Improves Balance Function for People with Osteoporosis
This meta-analysis of exercise interventions for osteoporosis indicates significant improvements in balance function. Larger effect sizes we…
Specific types of exercise programs can significantly improve balance for people living with osteoporosis, especially when sessions are long…
Oct 11, 2026
TCM combined with Western therapy improves BMD and FEV1 in patients with COPD and osteoporosis
Pulmonology & Critical Care Meta-analysis
TCM combined with Western therapy improves BMD and FEV1 in patients with COPD and osteoporosis Traditional Chinese Medicine may help lung and bone health
This meta-analysis of 944 patients found that combining Traditional Chinese Medicine (TCM) with Conventional Western medical therapy (CWMT) …
Adding Traditional Chinese Medicine to standard care may improve lung function and bone density for patients with COPD and osteoporosis.
Oct 6, 2026
Osteoporosis prevalence is 22.0% and low bone mass is 41.7% in men with prostate cancer
Oncology Meta-analysis
Osteoporosis prevalence is 22.0% and low bone mass is 41.7% in men with prostate cancer Prostate Cancer Treatment Linked to Higher Risk of Bone Loss
This meta-analysis of 91,913 adult men with prostate cancer found a 22.0% prevalence of osteoporosis and 41.7% prevalence of low bone mass. …
Men undergoing treatment for prostate cancer may face a significant risk of low bone mass and osteoporosis during their care.
Oct 6, 2026